Compare SMSI & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMSI | EDSA |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 12.8M |
| IPO Year | 1995 | N/A |
| Metric | SMSI | EDSA |
|---|---|---|
| Price | $0.62 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 105.9K | 28.5K |
| Earning Date | 11-05-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,359,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $1.55 |
| 52 Week High | $1.95 | $4.49 |
| Indicator | SMSI | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 34.16 |
| Support Level | $0.57 | $1.71 |
| Resistance Level | $0.65 | $1.82 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 59.45 | 4.17 |
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.